Compugen (CGEN) Competitors

$2.80 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.80 0.00 (-0.18%)

As of 05/22/2026 07:18 PM Eastern

CGEN vs. MRVI, CVAC, PURR, XERS, and CRVS

Should you buy Compugen stock or one of its competitors? MarketBeat compares Compugen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compugen include Maravai LifeSciences (MRVI), CureVac (CVAC), Hyperliquid Strategies (PURR), Xeris Biopharma (XERS), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

How does Compugen compare to Maravai LifeSciences?

Compugen (NASDAQ:CGEN) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Compugen had 15 more articles in the media than Maravai LifeSciences. MarketBeat recorded 16 mentions for Compugen and 1 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.64 beat Compugen's score of 0.14 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Maravai LifeSciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.2% of Compugen shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Compugen has a net margin of 47.97% compared to Maravai LifeSciences' net margin of -51.07%. Compugen's return on equity of 47.72% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Compugen presently has a consensus target price of $5.00, indicating a potential upside of 78.57%. Maravai LifeSciences has a consensus target price of $5.50, indicating a potential upside of 25.00%. Given Compugen's stronger consensus rating and higher probable upside, research analysts clearly believe Compugen is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Maravai LifeSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Compugen has a beta of 2.79, meaning that its share price is 179% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Compugen has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.64	$35.34M	$0.37	7.57
Maravai LifeSciences	$185.74M	6.12	-$130.77M	-$0.71	N/A

Summary

Compugen beats Maravai LifeSciences on 12 of the 16 factors compared between the two stocks.

How does Compugen compare to CureVac?

CureVac (NASDAQ:CVAC) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

17.3% of CureVac shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Compugen's net margin of 47.97%. Compugen's return on equity of 47.72% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Compugen	47.97%	47.72%	27.51%

CureVac has higher earnings, but lower revenue than Compugen. CureVac is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Compugen	$72.76M	3.64	$35.34M	$0.37	7.57

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Compugen has a beta of 2.79, suggesting that its share price is 179% more volatile than the broader market.

In the previous week, Compugen had 16 more articles in the media than CureVac. MarketBeat recorded 16 mentions for Compugen and 0 mentions for CureVac. Compugen's average media sentiment score of 0.14 beat CureVac's score of 0.00 indicating that Compugen is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Compugen	Neutral

CureVac currently has a consensus target price of $6.83, suggesting a potential upside of 46.64%. Compugen has a consensus target price of $5.00, suggesting a potential upside of 78.57%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Compugen beats CureVac on 12 of the 17 factors compared between the two stocks.

How does Compugen compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Compugen (NASDAQ:CGEN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Hyperliquid Strategies currently has a consensus price target of $9.25, suggesting a potential upside of 20.60%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 78.57%. Given Compugen's stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Compugen had 7 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 16 mentions for Compugen and 9 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 0.57 beat Compugen's score of 0.14 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Compugen has higher revenue and earnings than Hyperliquid Strategies. Hyperliquid Strategies is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,032.54	-$16.01M	-$7.37	N/A
Compugen	$72.76M	3.64	$35.34M	$0.37	7.57

Hyperliquid Strategies has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Compugen has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market.

Compugen has a net margin of 47.97% compared to Hyperliquid Strategies' net margin of 0.00%. Compugen's return on equity of 47.72% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Compugen	47.97%	47.72%	27.51%

Summary

Compugen beats Hyperliquid Strategies on 14 of the 16 factors compared between the two stocks.

How does Compugen compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Compugen has lower revenue, but higher earnings than Xeris Biopharma. Compugen is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.66	$550K	$0.06	103.17
Compugen	$72.76M	3.64	$35.34M	$0.37	7.57

Compugen has a net margin of 47.97% compared to Xeris Biopharma's net margin of 3.81%. Xeris Biopharma's return on equity of 735.00% beat Compugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Compugen	47.97%	47.72%	27.51%

Xeris Biopharma currently has a consensus target price of $10.80, suggesting a potential upside of 74.47%. Compugen has a consensus target price of $5.00, suggesting a potential upside of 78.57%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe Compugen is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Xeris Biopharma has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Compugen has a beta of 2.79, meaning that its stock price is 179% more volatile than the broader market.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 6.5% of Xeris Biopharma shares are held by company insiders. Comparatively, 9.5% of Compugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Compugen had 15 more articles in the media than Xeris Biopharma. MarketBeat recorded 16 mentions for Compugen and 1 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.84 beat Compugen's score of 0.14 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Compugen beats Xeris Biopharma on 10 of the 17 factors compared between the two stocks.

How does Compugen compare to Corvus Pharmaceuticals?

Compugen (NASDAQ:CGEN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Compugen presently has a consensus price target of $5.00, indicating a potential upside of 78.57%. Corvus Pharmaceuticals has a consensus price target of $33.33, indicating a potential upside of 164.34%. Given Corvus Pharmaceuticals' higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Compugen has a beta of 2.79, suggesting that its share price is 179% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Compugen has a net margin of 47.97% compared to Corvus Pharmaceuticals' net margin of 0.00%. Compugen's return on equity of 47.72% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

12.2% of Compugen shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Compugen has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.64	$35.34M	$0.37	7.57
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

In the previous week, Compugen had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 16 mentions for Compugen and 13 mentions for Corvus Pharmaceuticals. Compugen's average media sentiment score of 0.14 beat Corvus Pharmaceuticals' score of 0.14 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compugen beats Corvus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Compugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEN vs. The Competition

Export

Metric	Compugen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$264.75M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	7.57	18.74	21.21	25.65
Price / Sales	3.64	323.98	554.38	86.31
Price / Cash	7.49	125.17	43.49	56.67
Price / Book	2.77	7.09	10.37	7.14
Net Income	$35.34M	$24.45M	$3.57B	$335.98M
7 Day Performance	2.41%	6.38%	6.40%	4.15%
1 Month Performance	-9.68%	2.43%	3.53%	2.54%
1 Year Performance	93.10%	62.98%	34.04%	35.06%

Compugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEN Compugen	3.9223 of 5 stars	$2.80 flat	$5.00 +78.6%	+93.1%	$264.75M	$72.76M	7.57	70	Analyst Downgrade Gap Down
MRVI Maravai LifeSciences	3.0769 of 5 stars	$4.09 +0.1%	$5.50 +34.6%	+98.2%	$1.06B	$185.74M	N/A	610	Analyst Upgrade
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880
PURR Hyperliquid Strategies	2.9594 of 5 stars	$7.62 +9.9%	$8.82 +15.7%	N/A	$1.03B	$1M	N/A	N/A	Gap Up
XERS Xeris Biopharma	2.9835 of 5 stars	$5.94 -1.2%	$10.80 +82.0%	+28.2%	$1.02B	$291.85M	98.58	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEN) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compugen (CGEN) Competitors

CGEN vs. MRVI, CVAC, PURR, XERS, and CRVS

How does Compugen compare to Maravai LifeSciences?

Summary

How does Compugen compare to CureVac?

Summary

How does Compugen compare to Hyperliquid Strategies?

Summary

How does Compugen compare to Xeris Biopharma?

Summary

How does Compugen compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compugen (CGEN) Competitors

CGEN vs. MRVI, CVAC, PURR, XERS, and CRVS

How does Compugen compare to Maravai LifeSciences?

Does the media prefer CGEN or MRVI?

Do institutionals & insiders have more ownership in CGEN or MRVI?

Is CGEN or MRVI more profitable?

Do analysts prefer CGEN or MRVI?

Which has more risk & volatility, CGEN or MRVI?

Which has preferable valuation and earnings, CGEN or MRVI?

Summary

How does Compugen compare to CureVac?

Do insiders and institutionals have more ownership in CVAC or CGEN?

Is CVAC or CGEN more profitable?

Which has preferable earnings and valuation, CVAC or CGEN?

Which has more volatility and risk, CVAC or CGEN?

Does the media favor CVAC or CGEN?

Do analysts prefer CVAC or CGEN?

Summary

How does Compugen compare to Hyperliquid Strategies?

Do institutionals & insiders have more ownership in PURR or CGEN?

Do analysts recommend PURR or CGEN?

Does the media favor PURR or CGEN?

Which has preferable valuation & earnings, PURR or CGEN?

Which has more risk and volatility, PURR or CGEN?

Is PURR or CGEN more profitable?

Summary

How does Compugen compare to Xeris Biopharma?

Which has stronger earnings and valuation, XERS or CGEN?

Is XERS or CGEN more profitable?

Do analysts recommend XERS or CGEN?

Which has more risk & volatility, XERS or CGEN?

Do institutionals and insiders have more ownership in XERS or CGEN?

Does the media favor XERS or CGEN?

Summary

How does Compugen compare to Corvus Pharmaceuticals?

Do analysts rate CGEN or CRVS?

Which has more risk & volatility, CGEN or CRVS?

Is CGEN or CRVS more profitable?

Do institutionals & insiders believe in CGEN or CRVS?

Which has preferable earnings & valuation, CGEN or CRVS?

Does the media refer more to CGEN or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools